Emerging Company Profile

Notch’s $85M series A builds on Allogene deal for off-the-shelf, iPSC-derived cell therapies

Emerging Company Profile: Notch’s manufacturing leap could bring scale

Notch’s iPSC differentiation platform could enable the company to manufacture cell therapies at scale. 

Building on an early partnership with Allogene in blood cancers, Canadian start-up Notch has raised $85 million in a series A round designed to bring the